Crossmark

N-benzylbenzamide derivative (SBM685) as a novel MDR1 inhibitor for overcoming 5 fluorouracil resistance in gastric cancer through computational and in vitro analysis

Crossref DOI link: https://doi.org/10.1007/s12672-026-04767-x

Published Online: 2026-03-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Al Fayi, Majed

Dera, Ayed A. https://orcid.org/0000-0002-6248-8983
Funding

Funding for this research was provided by:

Deanship of Research and Graduate Studies at King Khalid University (RGP2/154/46)
License Information

Text and Data Mining valid from 2026-03-04

Version of Record valid from 2026-04-10
More Information

Article History

Received: 5 November 2025

Accepted: 2 March 2026

First Online: 4 March 2026

Declarations

:

: Not applicable. This study did not involve human participants or animals.

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below